In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.
first published: Mar 13, 2012 10:50 am
A collection of the most-viewed Moneycontrol videos.
Live: Broader markets outperform this week; Metal, realty top sectoral plays | Closing Bell
Trump Signals Major Breakthrough In Iran Deal, May Visit Islamabad Soon
Wall street continues rally, Asian markets trade soft | Brent Oil above $98 | Wipro Results
Buying Gold This Akshaya Tritiya? Don’t Make These Mistakes
